Clinical Trial Information Request for Protocol 2025P000250 Title A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC) PI Site Directions: Type your name, contact email and phone number (optional) into the boxes below then click Save to Submit your request for information about this study. Name Email Phone